Welcome to the international HTA database

Showing [21797 Records] Selected Records [0 Hits] [Clear]

Year	Source	Title
2018	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Cariprazine (schizophrenia) - Benefit assessment according to §35a Social Code Book V]
2018	Haute Autorite de sante (HAS)	[Treatment of superficial stomach cancer by endoscopic submucosal dissection (ESD)]
2018	NIHR Health Technology Assessment programme	What is the added value of ultrasound joint examination for monitoring synovitis in rheumatoid arthritis and can it be used to guide treatment decisions? A systematic review and cost-effectiveness analysis
2018	NIHR Health Services and Delivery Research programme	Understanding new models of care in local contexts: a systematic review using frameworks to examine pathways of change, applicability, and generalisability of the international research evidence
2018	NIHR Public Health Research (PHR) programme	Child food insecurity in the UK: a rapid review
2018	Norwegian Institute of Public Health (NIPH)	Therapist-supported internet therapy for mental disorders – a health technology assessment
2018	Institut national d'excellence en sante et en services sociaux (INESSS)	[Report: use of the prostate-specific antigen (PSA) test in prostate cancer screening in Québec]
2018	Institute for Clinical Effectiveness and Health Policy (IECS)	[Hydrotherapy in skeletal muscle disorders]
2018	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Benralizumab (asthma) - Addendum to Commission A18-11]
2018	Institute for Clinical Effectiveness and Health Policy (IECS)	[Dynamic stabilization with interspinous devices for spinal conditions]
2018	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Search for guidelines for the update of the DMP "type 1 diabetes"]
2018	Institut national d'excellence en sante et en services sociaux (INESSS)	[State of knowledge: equitable access to the psychotherapy services in Quebec]
2018	Institute for Clinical Effectiveness and Health Policy (IECS)	[Neuronavigator-guided brain neurosurgical procedures]
2018	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Fluticasone furoate/umeclidinium/vilanterol (COPD) - Addendum to Commission A18-15]
2018	Institute for Clinical Effectiveness and Health Policy (IECS)	[Music therapy in children with developmental disorders]
2018	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Ixekizumab (psoriatic arthritis) - Addendum to Commission A18-14]
2018	Institute for Clinical Effectiveness and Health Policy (IECS)	[Narrow band imaging (NBI) in diagnostic gastrointestinal endoscopy]
2018	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Extract from Cannabis sativa (spasticity due to multiple sclerosis) - Benefit assessment according to §35a Social Code Book V (expiry of the decision)]
2018	Institut national d'excellence en sante et en services sociaux (INESSS)	[Report: optimal service trajectory for children, adolescents and young adults with attention deficit disorder with or without hyperactivity (ADHD) or related problems]
2018	Institute for Clinical Effectiveness and Health Policy (IECS)	[Hormone receptor testing in breast cancer]
2018	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Tofacitinib (rheumatoid arthritis) - Benefit assessment according to §35a Social Code Book V (expiry of the decision)]
2018	NIHR Health Technology Assessment programme	Factors associated with hospital emergency readmission and mortality rates in patients with heart failure or chronic obstructive pulmonary disease: a national observational study
2018	Institute for Clinical Effectiveness and Health Policy (IECS)	[Vancomycin trough for therapeutic monitoring]
2018	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Screening for depression]
2018	Adelaide Health Technology Assessment (AHTA)	Extended half-life clotting factor concentrates for the treatment of haemophilia A and B
2018	Institute for Clinical Effectiveness and Health Policy (IECS)	[Biofeedback in adults with fecal and/or urinary incontinence]
2018	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Concept for a national health portal]
2018	Medical Services Advisory Committee (MSAC)	Computed tomography coronary angiogram - multi-slice computed tomography coronary angiography in the visualisation of coronary arteries
2018	NIHR Health Technology Assessment programme	Interventions to improve antimicrobial prescribing of doctors in training (IMPACT): a realist review
2018	Adelaide Health Technology Assessment (AHTA)	Heritable mutations which increase risk in colorectal and endometrial cancer
2018	Institute for Clinical Effectiveness and Health Policy (IECS)	[Vertebroplasty or kyphoplasty in osteoporotic vertebral fractures]
2018	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Biomarker-based tests for the decision for or against adjuvant systemic chemotherapy in primary breast cancer - Addendum to Commission D14-01]
2018	Adelaide Health Technology Assessment (AHTA)	Anti-Mullerian Hormone (AMH) testing for female patients who will or have received gonadotoxic treatment
2018	Institute for Clinical Effectiveness and Health Policy (IECS)	[Trabecular micro bypass stent for glaucoma]
2018	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Hydrocortisone (adrenal insufficiency) - Benefit assessment according to §35a Social Code Book V]
2018	Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA)	Osimertinib (Tagrisso®) for the initial treatment of EGFR-mutated advanced non–small-cell lung cancer (NSCLC)
2018	Norwegian Institute of Public Health (NIPH)	EXOGEN™ in the treatment of non-union fractures. A single technology assessment
2018	Institute for Clinical Effectiveness and Health Policy (IECS)	[Lumacaftor/Ivacaftor therapy in cystic fibrosis]
2018	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Ertugliflozin/sitagliptin (type 2 diabetes mellitus) - Benefit assessment according to §35a Social Code Book V]
2018	Norwegian Institute of Public Health (NIPH)	Effectiveness and safety of nitrous oxide as sedation regimen in children – an HTA
2018	Institute for Clinical Effectiveness and Health Policy (IECS)	[Cognitive rehabilitation in secondary cognitive impairment]
2018	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Rurioctocog alfa pegol (haemophilia A) - Benefit assessment according to §35a Social Code Book V]
2018	Norwegian Institute of Public Health (NIPH)	Autologous hematopoietic stem cell transplantation (AHSCT) for Diffuse Systemic Sclerosis. Health Technology Assessment
2018	Institut national d'excellence en sante et en services sociaux (INESSS)	[Report: cardiopulmonary resuscitation (CPR) in a context of community-based naloxone administration for opioid overdose]
2018	Institute for Clinical Effectiveness and Health Policy (IECS)	[Scalp cooling in patients at risk of chemotherapy-induced alopecia]
2018	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Darvadstrocel (perianal fistulas in Crohn disease) - Assessment according to §35a (para. 1., sentence 11) Social Code Book V]
2018	Norwegian Institute of Public Health (NIPH)	The MicraTM Transcatheter Pacing System, a leadless pacemaker, in patients indicated for single-chamber ventricular pacemaker implantation: A single technology assessment
2018	Institute for Clinical Effectiveness and Health Policy (IECS)	[Negative-pressure wound therapy for chronic wounds]
2018	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Bosutinib (chronic myeloid leukaemia) - Benefit assessment according to §35a Social Code Book V]
2018	NIHR Health Technology Assessment programme	A staff training intervention to improve communication between people living with dementia and health-care professionals in hospital: the VOICE mixed-methods development and evaluation study
2018	Norwegian Institute of Public Health (NIPH)	177Lutetium-based peptide receptor radionuclide therapy for treating neuroendocrine tumours: a health technology assessment
2018	Institute for Clinical Effectiveness and Health Policy (IECS)	[Vitamin D - population screening and supplementation in populations with deficit]
2018	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Emicizumab (haemophilia A) - Addendum to Commission A18-20]
2018	Norwegian Institute of Public Health (NIPH)	Diagnostic accuracy, clinical effectiveness and budget impact of screening BRCA1/2 mutation carriers by MRI. A health technology assessment
2018	Institute for Clinical Effectiveness and Health Policy (IECS)	[Negative-pressure wound therapy]
2018	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Cariprazine (schizophrenia) - Addendum to Commission A18-25]
2018	NIHR Health Technology Assessment programme	Nurse staffing levels, missed vital signs and mortality in hospitals: retrospective longitudinal observational study.
2018	Norwegian Institute of Public Health (NIPH)	Bariatric surgery for Type 2 Diabetes and a body mass index below 35
2018	Institute for Clinical Effectiveness and Health Policy (IECS)	[Positron emission tomography (pet) for routine follow-up of selected neoplasms]
2018	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Dolutegravir/rilpivirine (HIV infection) - Benefit assessment according to §35a Social Code Book V]
2018	Institut national d'excellence en sante et en services sociaux (INESSS)	[State of practice: a profile of the practices adopted in Quebec to facilitate the transition to adulthood of young people who reside in an alternative living facility]
2018	Institute for Clinical Effectiveness and Health Policy (IECS)	[Rituximab for patients with diagnosed chronic neuromyelitis, myasthenia gravis and chronic inflammatory demyelinating polyneuropathy]
2018	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Cabozantinib (renal cell carcinoma) - Benefit assessment according to §35a Social Code Book V]
2018	Institute for Clinical Effectiveness and Health Policy (IECS)	[Flash glucose monitoring system in diabetes mellitus patients]
2018	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Nivolumab (melanoma) - Benefit assessment according to §35a Social Code Book V (expiry of the decision)]
2018	Institut national d'excellence en sante et en services sociaux (INESSS)	[State of knowledge: strategies to optimize the appropriateness of MRI and CT requests - strategies and tools for optimal use]
2018	Institute for Clinical Effectiveness and Health Policy (IECS)	[Ceftazidime/avibactam in severe infections]
2018	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Olaparib (ovarian, fallopian tube, peritoneal cancer) - Benefit assessment according to §35a Social Code Book V]
2018	Swiss Federal Office of Public Health (FOPH)	Knee arthroscopy for the treatment of degenerative changes
2018	Institut national d'excellence en sante et en services sociaux (INESSS)	[Report: surgical treatment of the esophagus - quality and accessibility in Quebec]
2018	Institute for Clinical Effectiveness and Health Policy (IECS)	[FilmArray® in Acute Respiratory Infections and Sepsis]
2018	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Screening for hepatitis B]
2018	Institut national d'excellence en sante et en services sociaux (INESSS)	[State of knowledge: mild traumatic brain injury, knowledge update in preparation for the revision of the ministerial orientations for mild traumatic brain injury (2005-2010)]
2018	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Screening for hepatitis C]
2018	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Amyloid PET in dementia of unclear aetiology]
2018	NIHR Health Technology Assessment programme	Systematic review of treatment of dry age-related macular degeneration and Stargardt's disease
2018	Institut national d'excellence en sante et en services sociaux (INESSS)	[State of practice in pediatric trauma care: patients admitted to the designated facilities of the trauma care network between 2010 and 2015]
2018	Institute for Clinical Effectiveness and Health Policy (IECS)	[Implantable cardiac defibrillator for primary prevention of sudden death]
2018	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Pertuzumab (breast cancer) - Benefit assessment according to §35a Social Code Book V]
2018	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Amyloid PET in dementia of unclear aetiology (Addendum to Commission E18-03)]
2018	Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA)	Daratumumab (Darzalex®) in combination with bortezomib, melphalan and prednisone for untreated myeloma
2018	Institute for Clinical Effectiveness and Health Policy (IECS)	[Transcatheter aortic valve implantation for severe aortic stenosis]
2018	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Bictegravir/emtricitabine/tenofovir alafenamide (HIV infection) - Benefit assessment according to §35a Social Code Book V]
2018	NIHR Health Technology Assessment programme	Screening women aged 65 years or over for abdominal aortic aneurysm: a modelling study and health economic evaluation
2018	Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA)	Re-orientation of the Austrian parent-child preventive care programme. Part XI: Further development of the mother-child-pass: Screening recommendations of the expert working group for pregnancy, puerperium and early childhood (0-6 years)
2018	Institute for Clinical Effectiveness and Health Policy (IECS)	[Aortic valve replacement with rapid deployment or sutureless valves]
2018	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Ipilimumab (melanoma) - Benefit assessment according to §35a Social Code Book V]
2018	Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA)	Stereotactic radiotherapy, proton therapy and irreversible electroporation for the treatment of localised prostate cancer
2018	Institute for Clinical Effectiveness and Health Policy (IECS)	[Dipeptidyl peptidase-4 (dpp4) inhibitors in diabetes mellitus]
2018	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Velmanase alfa (enzyme replacement treatment for mild to moderate alpha-mannosidosis) - Assessment according to §35a (para. 1., sentence 11) Social Code Book V]
2018	Swedish Agency for Health Technology Assessment and Assessment of Social Services (SBU)	[Patient Health Questionnaire- 9, PHQ-9, for depression screening in adults]
2018	Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA)	Endobronchial valve implantation for emphysema. Update 2018
2018	Institute for Clinical Effectiveness and Health Policy (IECS)	[Single-use negative pressure wound therapy for acute and chronic wounds]
2018	Andalusian Health Technology Assessment Area (AETSA)	[Epigenetic profile for the identification of primary cancer of unknown origin]
2018	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Tofacitinib (rheumatoid arthritis) - Addendum to Commission A18-28]
2018	Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA)	High-intensity focused ultrasound for the treatment of prostate cancer. 1st Update 2018
2018	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Osimertinib (non-small cell lung cancer) - Benefit assessment according to §35a Social Code Book V]
2018	Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA)	(Percutaneous) left atrial appendage closure for the prevention of thromboembolic events in patients with atrial fibrillation. 3rd Update 2018
2018	Institute for Clinical Effectiveness and Health Policy (IECS)	[Tenofovir alafenamide in patients with HIV diagnosis]
2018	Andalusian Health Technology Assessment Area (AETSA)	[Point of care test for differential diagnosis of virus versus bacteria in acute respiratory tract infection]